Apeiron Therapeutics is a clinical-stage biopharmaceutical company focused on developing biomarker-driven therapeutics for cancer. Leveraging structure-based, AI-driven drug design, Apeiron develops best-in-class and first-in-class small molecule therapies aimed at improving patient outcomes. By integrating cutting-edge artificial intelligence with deep expertise in drug discovery, Apeiron advances a robust pipeline of targeted cancer treatments designed to address unmet medical needs.